Compare

Cartalax vs Thymosin Alpha-1

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Cartalax

1906 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 70% · Mixed 12% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
-151
Energy
-31
Mood
-61
Focus
-155
Sleep quality
-167

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
-55
Dizziness
-132
Fatigue
-96
Nausea
-159
Water retention
-167

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.025–5 mg

0.025–0.05 mg
1
0.05–0.1 mg
10
0.1–0.2 mg
18
0.2–0.4 mg
25
0.4–0.6 mg
32
0.6–1 mg
21
1–2 mg
12
2–3 mg
8
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing30stacking13side effects36cartalax14

How repeat users are trending

Among repeat reporters, 65% said they felt similar to their last entry, 38% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 419 repeat reporters

Thymosin Alpha-1

1526 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 50% · Mixed 40% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
93
Lean mass
89
Joint comfort
89
Recovery
134
Digestive comfort
94

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
189
Appetite loss
169
Injection site reaction
54
Anxiety
129
Flushing
94

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.025–3 mg

0.025–0.05 mg
1
0.05–0.1 mg
10
0.1–0.2 mg
18
0.2–0.4 mg
25
0.4–0.6 mg
28
0.6–1 mg
19
1–2 mg
11
2–3 mg
8

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing50stacking13side effects16thymosin alpha-19

How repeat users are trending

Among repeat reporters, 60% said they felt similar to their last entry, 42% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 336 repeat reporters

Sources (8)

Published sources linked on the Cartalax and Thymosin Alpha-1 wiki pages.

  1. PubMed

    Cartilage bioregulatory peptide in osteoarthritis models (preclinical review)

    Khavinson VK, et al. Adv Gerontol. 2014

    Source
    Wiki study page →
  2. PubMed

    Thymosin alpha 1: A comprehensive review of the literature

    Romani L, Moretti S, Fallarino F, et al. Expert Opin Biol Ther. 2020

    Source
    Wiki study page →
  3. PubMed

    Thymosin alpha 1: past clinical experience and future promise

    Tuthill C, Rios I, McBeath R. Ann N Y Acad Sci. 2010

    Source
    Wiki study page →
  4. PubMed

    Thymosin alpha 1 as adjuvant therapy for melanoma and other cancers

    Garaci E, Pica F, Serafino A, et al. Ann N Y Acad Sci. 2014

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Thymosin alpha-1 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. PubMed

    Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach

    Naylor PH, Mutchnick MG. Journal of viral hepatitis. 2018

    Source
    Wiki study page →
  7. PubMed

    Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

    Al-Mahtab M, Bazinet M, Vaillant A. PloS one. 2016

    Source
    Wiki study page →